Reversible pituitary insufficiency due to bexarotene therapy in a patient with mycosis fungoides.
Department of Endocrinology and Metabolism, Ondokuz Mayis University Medical School, Kurupelit, 55139, Samsun, Turkey, hulusi.atmaca@omu.edu.tr.
Hulusi
H
Atmaca
Ismail
I
Islek
Nilgün
N
Sentürk
D000309:Adrenal Insufficiency / Q000139:chemically induced; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077610:Bexarotene; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007006:Hypogonadism / Q000139:chemically induced; D007018:Hypopituitarism / Q000139:chemically induced*; D007037:Hypothyroidism / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene